Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT Trial in Chronic Coronary Syndrome
NCT07577518Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of carvedilol in Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Seoul National University Hospital. Primary endpoints: Patient-oriented composite outcome at 5 years and Seattle Angina Questionnaire-7 Summary Score at 12 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
carvedilol
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NCT07577518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07577518.